Tumor buster - where will the CAR-T cell therapy ‘missile’ go?

被引：0
作者：
Chunrun Qu
Hao Zhang
Hui Cao
Lanhua Tang
Haoyang Mo
Fangkun Liu
Liyang Zhang
Zhenjie Yi
Lifu Long
Luzhe Yan
Zeyu Wang
Nan Zhang
Peng Luo
Jian Zhang
Zaoqu Liu
Weijie Ye
Zhixiong Liu
Quan Cheng
机构：
[1] Central South University,Department of Neurosurgery, Xiangya Hospital
[2] Central South University,XiangYa School of Medicine
[3] Central South University,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital
[4] Chongqing Medical University,Department of Neurosurgery, The Second Affiliated Hospital
[5] The Hospital of Hunan University of Chinese Medicine,Department of Psychiatry, The Second People’s Hospital of Hunan Province
[6] Hunan University of Chinese Medicine,The School of Clinical Medicine
[7] Central South University,Department of Oncology, Xiangya Hospital
[8] Harbin Medical University,One
[9] Southern Medical University,third Lab, College of Bioinformatics Science and Technology
[10] The First Affiliated Hospital of Zhengzhou,Department of Oncology, Zhujiang Hospital
[11] Central South University,Department of Interventional Radiology
来源：
Molecular Cancer | / 21卷
关键词：
CAR-T cell; Immunotherapy; Target; Cancer; Personalized treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing technology represents a significant breakthrough in personalized immunotherapy for human cancer. This strategy uses genetic modification to enable T cells to target tumor-specific antigens, attack specific cancer cells, and bypass tumor cell apoptosis avoidance mechanisms to some extent. This method has been extensively used to treat hematologic diseases, but the therapeutic effect in solid tumors is not ideal. Tumor antigen escape, treatment-related toxicity, and the immunosuppressive tumor microenvironment (TME) limit their use of it. Target selection is the most critical aspect in determining the prognosis of patients receiving this treatment. This review provides a comprehensive summary of all therapeutic targets used in the clinic or shown promising potential. We summarize CAR-T cell therapies’ clinical trials, applications, research frontiers, and limitations in treating different cancers. We also explore coping strategies when encountering sub-optimal tumor-associated antigens (TAA) or TAA loss. Moreover, the importance of CAR-T cell therapy in cancer immunotherapy is emphasized.
引用
收藏
相关论文
共 1189 条
[1]  
Wang S(2021)Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors BMC Med 19 140-e178
[2]  
Sun J(2020)CAR T cells: continuation in a revolution of immunotherapy Lancet Oncol 21 e168-152
[3]  
Chen K(2017)CAR T cell therapy for solid tumors Annu Rev Med 68 139-398
[4]  
Singh AK(2017)Engineering CAR-T cells Biomark Res 5 22-509
[5]  
McGuirk JP(2013)The basic principles of chimeric antigen receptor design Cancer Discov 3 388-2152
[6]  
Newick K(2015)The pharmacology of second-generation chimeric antigen receptors Nat Rev Drug Discov 14 499-1154
[7]  
O'Brien S(2010)Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors Haematologica 95 2144-1438.e11
[8]  
Moon E(2020)Recent advances in CAR-T cell engineering J Hematol Oncol 13 86-1852
[9]  
Zhang C(2015)TRUCKs: the fourth generation of CARs Expert Opin Biol Ther 15 1145-E458
[10]  
Liu J(2018)Universal chimeric antigen receptors for multiplexed and logical control of T cell responses Cell 173 1426-7631
12345678910